ChromaDex (NASDAQ:CDXC - Get Free Report) had its target price upped by Roth Mkm from $4.25 to $6.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the stock. Roth Mkm's price target indicates a potential upside of 50.75% from the stock's previous close.
Separately, StockNews.com assumed coverage on shares of ChromaDex in a research report on Sunday, March 3rd. They issued a "strong-buy" rating for the company.
Get Our Latest Report on CDXC
ChromaDex Stock Down 5.5 %
NASDAQ CDXC traded down $0.23 on Tuesday, hitting $3.98. The stock had a trading volume of 451,778 shares, compared to its average volume of 250,626. ChromaDex has a one year low of $1.25 and a one year high of $4.65. The stock has a market cap of $299.73 million, a price-to-earnings ratio of -56.85 and a beta of 1.98. The company's 50-day moving average is $2.28 and its two-hundred day moving average is $1.72.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Connor Clark & Lunn Investment Management Ltd. lifted its stake in ChromaDex by 121.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,031 shares of the company's stock valued at $121,000 after purchasing an additional 45,618 shares during the last quarter. Gabelli Funds LLC lifted its stake in ChromaDex by 9.1% during the third quarter. Gabelli Funds LLC now owns 180,000 shares of the company's stock valued at $263,000 after purchasing an additional 15,000 shares during the last quarter. Gamco Investors INC. ET AL lifted its stake in ChromaDex by 26.5% during the third quarter. Gamco Investors INC. ET AL now owns 259,850 shares of the company's stock valued at $379,000 after purchasing an additional 54,500 shares during the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in ChromaDex during the fourth quarter valued at approximately $118,000. Finally, Cox Capital Mgt LLC acquired a new stake in ChromaDex during the third quarter valued at approximately $136,000. 15.41% of the stock is currently owned by institutional investors.
About ChromaDex
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Further Reading
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
